MHRA Approves Wegovy for MASH Liver Disease in UK

If this sounds like several layers of medical jargon at once, it is. So let us strip it back. On 3 July 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, approved semaglutide, sold as Wegovy, for adults with metabolic-associated steatohepatitis, known as MASH, who have moderate-to-advanced liver fibrosis, which means scarring in the liver. That is a significant step because MASH is not a minor liver issue. It is a form of liver disease linked to fat build-up, inflammation and scarring, and it is more common in people with obesity, type 2 diabetes or raised blood lipid levels. According to the MHRA, this new approval gives doctors another treatment option for a condition that can become serious over time.

**What this means:** a medicine can be approved by the regulator and still not be available on the NHS straight away. That is where some of the confusion often starts, so it is worth slowing down here. The MHRA's job is to decide whether a medicine is safe enough and effective enough to be licensed for a particular use. In this case, the regulator has said yes to Wegovy for MASH in a defined group of adults. But patients with MASH cannot currently get semaglutide on the NHS for this condition, because the National Institute for Health and Care Excellence, or NICE, is still assessing whether it is clinically useful and good value for NHS funding.

MASH develops when too much fat in the liver leads to inflammation and then scarring. You may also hear people talk more generally about fatty liver disease, but MASH is the more serious version where the liver is being damaged, not just storing excess fat. That matters because the liver does a huge amount of quiet work for the body, from processing nutrients to helping remove waste. When scarring builds up, the liver cannot do that work as well. So although the name may sound technical, the problem itself is straightforward: ongoing damage to an organ the body depends on every day.

Wegovy is already authorised for other uses. Semaglutide has existing approvals for weight management in adults and adolescents, and for reducing cardiovascular events in adults. For MASH, it is prescribed alongside diet and exercise rather than instead of them. The drug belongs to a group called GLP-1 receptor agonists. In plain English, it copies the action of a hormone released after eating, which helps people feel fuller for longer and can reduce food cravings. That is one reason it has become widely known in discussions about obesity treatment, but in this case the story is about liver disease as well as weight.

There is another important phrase in the MHRA announcement: conditional marketing authorisation. That does not mean the approval is fake or half-finished. It means the regulator is satisfied enough with the evidence to allow the medicine for this use now, while still requiring more confirmatory data from an ongoing study before full authorisation is considered. According to the MHRA, further results in adults with MASH and moderate-to-advanced liver scarring still need to be submitted. The agency has also said it will review new information on semaglutide at least once a year and update the official product information if needed. In other words, approval has been granted, but the checking does not stop here.

For patients, this is also a reminder that prescription medicines are not a social media trend. The MHRA says semaglutide for MASH should only be taken in consultation with a doctor. Treatment starts at 0.25 mg once a week and is stepped up gradually through 0.5 mg, 1 mg and 1.7 mg, with four weeks on each dose, before reaching a maintenance dose of 2.4 mg once weekly. The MHRA also says that for patients with obesity, defined here as a BMI above 30, the dose can be increased to 7.2 mg once weekly after at least four weeks on 2.4 mg. That sort of dose adjustment is exactly why medical supervision matters. It is not something to copy from a headline or a comment section.

**A useful distinction:** the MHRA decides whether a medicine can be licensed. NICE decides whether the NHS should provide it routinely. Those two decisions are linked, but they are not the same decision. So where are we now? NICE is still appraising semaglutide for MASH, looking at both clinical benefit and cost effectiveness. Until that process is complete, NHS access for this specific liver condition is not in place. For readers trying to make sense of the news, the simplest version is this: the science has moved forward, but the route into everyday patient care is still being worked through.

As with any medicine, side effects matter. The most common ones listed by the MHRA are gastrointestinal problems such as nausea, diarrhoea, constipation and vomiting. Anyone who thinks they may be having a side effect is being advised to speak to a doctor, pharmacist or nurse, and they can also report it through the Yellow Card scheme. That final point is easy to miss, but it is one of the most important. Medicines are still monitored after approval, and patient reporting is part of how safety systems keep working. So the story here is not just that Wegovy has been approved for MASH in the UK. It is that regulators, doctors, patients and NHS decision-makers all have a part in what happens next.